)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
China Isotope & Radiation Corporation
China Isotope & Radiation Corporation (1763) investor relations material
China Isotope & Radiation Corporation H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary28 Aug, 2026
Executive summary
Revenue for the first half of 2026 reached RMB2,993.8 million, up 4.4% year-over-year, driven by growth in nuclear medicines, nuclear medical equipment, and radioactive source and application segments.
Net profit was RMB332.2 million, up 2.1% year-over-year; net profit attributable to the parent company was RMB159.0 million, down 1.2% due to tax adjustments, business restructuring, and exchange losses.
Gross margin declined to 49.4% from 51.7% year-over-year, mainly due to changes in revenue structure.
The Board proposed an interim dividend of RMB0.0994 per share, totaling RMB31.8 million, subject to shareholder approval.
Financial highlights
Operating revenue: RMB2,993.8 million (up 4.4% year-over-year).
Gross profit: RMB1,480.1 million (in line with prior year); gross margin: 49.4% (down 2.3 percentage points year-over-year).
Net profit: RMB332.2 million (up 2.1% year-over-year); net profit attributable to parent: RMB159.0 million (down 1.2% year-over-year).
Earnings per share: RMB0.5030.
Total assets: RMB16,080.2 million; total liabilities: RMB7,732.5 million; total equity: RMB8,347.7 million as of 30 June 2026.
Adjusted net gearing ratio: 35.6%; quick ratio: 1.5x.
Capital expenditures: RMB245.8 million.
Outlook and guidance
Plans to expand the nationwide network of pharmaceutical centers to 37, covering over 95% of the population.
Focus on accelerating self-sufficiency in isotope supply, expanding the nuclear medicine industrial chain, and deepening smart nuclear medicine solutions and digital transformation.
Continued investment in R&D, digital transformation, high-end equipment, and international market expansion.
Strategic emphasis on extending, supplementing, and strengthening the industrial chain, scientific innovation, and market development.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from China Isotope & Radiation Corporation
- 2025 revenue fell 5.1% and net profit dropped 24.4%, but gross margin rose to 50.4%.1763
H2 2025 - Net profit rose 11.2% on 1.7% revenue growth, with strong export gains and a proposed interim dividend.1763H1 2025
- Revenue and net profit increased, with strong growth in radioactive source products and an interim dividend.1763H1 2024
- Revenue and net profit rose double digits, with strong growth in equipment and international business.1763H2 2024
Next China Isotope & Radiation Corporation earnings date
H2 202626 Mar, 2027
China Isotope & Radiation Corporation
Next China Isotope & Radiation Corporation earnings date
H2 202626 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
China Isotope & Radiation Corporation is a China-based company engaged in the research, production, and distribution of isotope and radiation-related products. The company operates across multiple segments, including nuclear medicine, radiation therapy, industrial irradiation, and radioactive source applications. It provides radiopharmaceuticals, medical imaging solutions, and radiation-based sterilization services for healthcare, industrial, and agricultural sectors. China Isotope & Radiation Corporation is headquartered in Beijing, China, and its shares are listed on the HKEX.